

NeuroNEXT Network

Standard Operating Procedure (SOP)


Investigational Site Staff Training

Version 3.0


SOP NN PM 504

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by

Signature and Date:   I approve this document 15-Feb-2023 8:18:08 AM PST <small>C68AC8DD80334CF982AED1200765F147</small>	15-Feb-2023
Name and Title: Christopher S. Coffey, PhD (DCC Principal Investigator)	
Signature and Date:   I approve this document 17-Feb-2023 9:39:15 AM EST <small>9F8FE4180E504C6AB0A67B835E80C644</small>	17-Feb-2023
Name and Title: Merit E. Cudkowicz, MD MSc (CCC Principal Investigator)	
Signature and Date:   I approve this document 15-Feb-2023 8:45:01 PM EST <small>58FE690F6BCA4F2390E3DA15BCE3F578</small>	15-Feb-2023
Name and Title: Marianne Chase, BA (CCC Senior Director of Clinical Trials Operations)	

Signature and Date:

DocuSigned by DIXIE ECKLUND
 | I approve this document
15-Feb-2023 | 11:49:43 AM PST
7006AF622EFC40B6A067A08EC02591B6

15-Feb-2023

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

Signature and Date:

DocuSigned by Stacey Grabert
 | I approve this document
22-Feb-2023 | 11:22:36 AM EST
60CC52B0747A44E6B2208D8D880699C0

22-Feb-2023

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

Signature and Date:

DocuSigned by Joan Ohayon
 | I approve this document
15-Feb-2023 | 9:02:14 AM PST
72C6AAFD8CC4485582ACA0700072901A

15-Feb-2023

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

NN PM 504

NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR INVESTIGATIONAL SITE STAFF TRAINING

1. POLICY

For all NeuroNEXT Network studies, each participating Clinical Study Site (CSS) will undergo ongoing staff training on:

- all aspects of the study protocol;
- scientific rationale for the study;
- management of anticipated adverse events applicable to the Investigational Product;
- adverse event management;
- principles of Good Clinical Practice (GCP); and
- other study-related topics, as determined by the CCC, the DCC, and the PPI (or designee).

Each CSS will undergo re-training as needed throughout the course of a clinical investigation. New site staff members that join study participation after initial CSS training has occurred will be trained before they are permitted to engage in any study-related tasks. The CCC and DCC will maintain records of CSS trainings / certifications.

2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC) within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

3. ROLES AND RESPONSIBILITIES

The NeuroNEXT CCC and DCC are responsible for verifying that each participating CSS site meets all applicable requirements for facilities, personnel, Good Clinical Practices (GCP) compliance, and regulatory compliance prior to initiation of the clinical investigation at that site, and maintaining records of trainings/certifications.

The CCC is responsible for issuing a written notification of CSS activation once all required study start-up training and documentation is completed for a CSS participating in a given study. The CCC is also responsible for forwarding the notification of Single Institutional Review Board (SIRB) approval/activation and approved Informed Consent Forms to the CSS.

The CCC and DCC are responsible for ensuring that all site personnel who will participate in the conduct of the clinical investigation have completed a protocol training session prior to the initiation of that site staff member's participation in the clinical investigation.

The DCC is responsible for ensuring that all site personnel who perform data entry into the electronic data entry system have completed Data Entry Certification prior to the initiation of data entry activities.

The CCC and DCC are responsible for reviewing the qualifications of site personnel who will be performing specified clinical research procedures, and for verifying the training of site personnel in these procedures prior to certification of the CSS and before any staff member begins newly delegated tasks.

The CCC and DCC are responsible for confirming, prior to CSS certification, that any laboratories at participating sites that perform laboratory processing or point-of-care testing for the clinical investigation are compliant with Good Laboratory Practices and institutional guidelines.

The CCC, in collaboration with the DCC and the PPI as needed, is responsible for creating and providing appropriate study materials and checklists to aid in conduct of a clinical investigation to all CSS.

The CCC is responsible for informing the Protocol Principal Investigator (PPI) of any participating CSS investigator who has failed to maintain appropriate licensure or certification requirements, as specified in applicable regulations.

When appropriate (or as requested by the PPI), the CCC and the DCC are responsible for providing CSS training and retraining on the following areas using an appropriate training medium:

- protocol compliance;
- clinical research procedures;
- adherence to GCP; and
- regulatory requirements.

4. APPLICABLE REGULATIONS AND GUIDELINES

ICH E6, 5.5	Trial Management, Data Handling and Record Keeping
ICH E6, 5.15	Record Access
ICH E6, 8.0	Essential Documents for the Conduct of a Clinical Trial

5. REFERENCES TO OTHER APPLICABLE SOPS

NN RA 202	Trial Master File Maintenance
NN RA 203	Site Regulatory File Maintenance
NN SS 402	Site Initiation Visits and Site Training
NN SS 403	Routine Monitoring Visits
NN SS 404	Site Performance Monitoring
NN SS 405	Study Closeout Visits
NN PM 503	Study Materials Development
NN DM 1005	Data Collection and Data Handling

6. ATTACHMENTS AND REFERENCES

NN PM 504 – A	Document History
---------------	------------------

7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CAPA	Corrective Action and Preventative Action plan
CCC	Clinical Coordinating Center at Massachusetts General Hospital
CSS	Clinical Study Site
DCC	Data Coordinating Center at The University of Iowa
FDA	U.S. Food and Drug Administration
GCP	Good Clinical Practice
ICH	International Council for Harmonisation
PPI	Protocol Principal Investigator
SIRB	Single Institutional Review Board

8. SPECIFIC PROCEDURES

A. Site and Personnel Training

#	Who	Task	Attachment	Related SOP
1.	CCC, DCC, and PPI or designee	Determine which trainings, certifications, and regulatory requirements are to be met by the participating CSS prior to initiation of the clinical investigation, and throughout the duration of the investigation.		NN RA 202 NN SS 402
2.	CCC	Confirm that the site has completed training in all applicable GCP guidance documents, clinical and laboratory procedures, data entry procedures, and use of study-related equipment or instrumentation.		NN SS 402 NN DM 1005
3.	CCC	Provide a written notice of approval and activation to each CSS that has completed all required training and site activation activities, along with the notification of SIRB approval/activation and the Informed Consent Form(s).		
4.	CCC	Maintain documentation of CSS and personnel trainings / certifications for each CSS in the study Trial Master File.		NN RA 202
5.	CSS	Maintain documentation of CSS and personnel training in the Site Regulatory Binder.		NN RA 203

B. Ongoing Site and Personnel Training

#	Who	Task	Attachment	Related SOP
1.	CCC, DCC, and PPI or designee	Develop requirements for scheduling ongoing trainings for participating CSS.		
2.	CCC, DCC	Provide on-site training or web-based training per schedule or 'for cause', as warranted.		NN SS 402 NN SS 404
3.	CCC, DCC Study Monitor	Periodically review any applicable instrumentation maintenance certifications to ensure that they are current.		NN SS 403
4.	CCC	Review certification-related documents for each participating CSS to ensure that they are accurate and complete.		NN SS 403
5.	DCC, CCC	Report lapses in certifications to the PPI, and follow up with the site to ensure that criteria for certification are re-established, or to initiate procedures for re-certification, when necessary.		NN SS 404
6.	DCC, CCC, and PPI or designee	If a site demonstrates a need for retraining, work with site personnel and the PPI to create a Corrective Action and Preventative Action (CAPA) plan to rectify any issues and perform retraining.		NN SS 404

Certificate Of Completion

Envelope Id: 3D5016D4CB384D979853A0974EAE8538 Status: Completed
Subject: Complete with DocuSign: NN PM 504 Investigational Site Staff Training v3.0.docx
Source Envelope:
Document Pages: 5 Signatures: 6 Envelope Originator:
Certificate Pages: 6 Initials: 0 Tania Leeder
AutoNav: Enabled TLEEDER@PARTNERS.ORG
Envelopeld Stamping: Disabled IP Address: 73.123.188.5
Time Zone: (UTC-05:00) Eastern Time (US & Canada)

Record Tracking

Status: Original Holder: Tania Leeder Location: DocuSign
2/15/2023 8:30:05 AM TLEEDER@PARTNERS.ORG

Signer Events

Christopher Coffey Signature Timestamp
christopher-coffey@uiowa.edu Christopher Coffey Sent: 2/15/2023 8:31:46 AM
Security Level: Email, Account Authentication Viewed: 2/15/2023 11:18:00 AM
(Required), Login with SSO Signed: 2/15/2023 11:18:10 AM

Signature Adoption: Pre-selected Style
Signature ID:
C68AC8DD-8033-4CF9-82AE-D1200765F147
Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 11:18:00 AM
ID: 44b389f2-50ca-4eb8-985d-b5c996b623fe

DIXIE ECKLUND
dixie-ecklund@uiowa.edu
Security Level: Email, Account Authentication
(Required), Login with SSO

DocuSigned by DIXIE ECKLUND
I approve this document
15-Feb-2023 | 11:49:43 AM PST
7006AF622EFC40B6A067A08EC02591B6

Sent: 2/15/2023 8:31:47 AM
Viewed: 2/15/2023 2:48:57 PM
Signed: 2/15/2023 2:49:46 PM

Signature Adoption: Drawn on Device
Signature ID:
7006AF62-2EFC-40B6-A067-A08EC02591B6
Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/15/2023 2:48:57 PM
ID: 7b73ba18-8b4c-496f-826e-9a73a269d970

Signer Events**Signature****Timestamp**

Joan Ohayon
ohayonj@ninds.nih.gov
Security Level: Email, Account Authentication
(Required)

Joan Ohayon

Sent: 2/15/2023 8:31:48 AM
Viewed: 2/15/2023 12:01:56 PM
Signed: 2/15/2023 12:02:16 PM

Signature Adoption: Pre-selected Style
Signature ID:
72C6AAFD-8CC4-4855-82AC-A0700072901A
Using IP Address: 156.40.137.188

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/13/2023 2:03:22 PM
ID: 385a0a53-0f0c-4395-88f6-d5700c36e050

Marianne Chase
MCHASE@mgh.harvard.edu
Sr Director, Clinical Trial Operations
Insight OBO The Massachusetts General Hospital
Security Level: Email, Account Authentication
(Required)

Marianne Chase


Sent: 2/15/2023 8:31:47 AM
Viewed: 2/15/2023 8:44:30 PM
Signed: 2/15/2023 8:45:04 PM

Signature Adoption: Pre-selected Style
Signature ID:
58FE690F-6BCA-4F23-90E3-DA15BCE3F578
Using IP Address: 73.114.253.109

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

Merit Cudkowicz
cudkowicz.merit@mgh.harvard.edu
Chief of Neurology
Security Level: Email, Account Authentication
(Required), Logged in


DocuSigned by Merit Cudkowicz
 | I approve this document
17-Feb-2023 | 9:39:15 AM EST
9F8FE4180E504C6AB0A67B835E80C644

Sent: 2/15/2023 8:31:47 AM
Viewed: 2/17/2023 9:39:06 AM
Signed: 2/17/2023 9:39:18 AM

Signature Adoption: Pre-selected Style
Signature ID:
9F8FE418-0E50-4C6A-B0A6-7B835E80C644
Using IP Address: 68.239.56.73

With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):
I approve this document

Electronic Record and Signature Disclosure:
Accepted: 2/17/2023 9:39:06 AM
ID: 300f5e4d-0a61-496e-8710-263010dc658b

Signer Events	Signature	Timestamp
Stacey Grabert sgrabert@mgh.harvard.edu Director QA Stacey Grabert Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 2/15/2023 8:31:48 AM Viewed: 2/22/2023 11:22:27 AM Signed: 2/22/2023 11:22:39 AM
Electronic Record and Signature Disclosure: Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b		
In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2/15/2023 8:31:48 AM
Certified Delivered	Security Checked	2/22/2023 11:22:27 AM
Signing Complete	Security Checked	2/22/2023 11:22:39 AM
Completed	Security Checked	2/22/2023 11:22:39 AM
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jhenrique@mgh.harvard.edu

To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.